Insider Buying: Anixa Biosciences (NASDAQ:ANIX) Director Buys $27,300.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) Director Lewis Titterton, Jr. bought 10,000 shares of Anixa Biosciences stock in a transaction on Thursday, September 10th. The stock was acquired at an average price of $2.73 per share, for a total transaction of $27,300.00. Following the transaction, the director directly owned 996,967 shares of the company’s stock, valued at approximately $2,721,719.91. This trade represents a 1.01% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Anixa Biosciences Stock Performance

Shares of Anixa Biosciences stock traded up $0.05 on Monday, reaching $2.81. The company had a trading volume of 74,892 shares, compared to its average volume of 194,359. The firm’s 50 day moving average price is $3.33 and its two-hundred day moving average price is $2.98. Anixa Biosciences Inc has a 52-week low of $2.32 and a 52-week high of $5.46. The firm has a market cap of $97.68 million, a PE ratio of -8.78 and a beta of 0.51.

Anixa Biosciences (NASDAQ:ANIX) last posted its earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). As a group, sell-side analysts predict that Anixa Biosciences Inc will post -0.31 EPS for the current year.

Hedge Funds Weigh In On Anixa Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in ANIX. NewEdge Advisors LLC acquired a new position in shares of Anixa Biosciences during the second quarter worth about $33,000. Sanctuary Advisors LLC acquired a new stake in Anixa Biosciences in the second quarter valued at approximately $29,000. Northwestern Mutual Wealth Management Co. purchased a new position in Anixa Biosciences in the second quarter worth approximately $29,000. Integrated Wealth Concepts LLC purchased a new position in Anixa Biosciences in the second quarter worth approximately $30,000. Finally, Cetera Investment Advisers acquired a new position in Anixa Biosciences during the 4th quarter worth approximately $35,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Zacks Research lowered shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Weiss Ratings cut shares of Anixa Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Citigroup restated a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Anixa Biosciences currently has a consensus rating of “Hold” and a consensus target price of $10.00.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.